Business
Nurix Therapeutics, Inc.: We have never generated revenue from product sales and may never be profitable.
Revenue increased 54.0% to $84.0M, while Net income decreased 36.6% to ($264.5M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $84.0MWatch
- Profitability — Net income ($264.5M)Watch
- Cash generation — Free cash flow ($263.5M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 19 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Nurix Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Collaboration revenue$54.0M
- License revenue$30.0M
Leadership changes
From Nurix Therapeutics, Inc.'s own filings, the day they're filed.
- Roy D. Baynes · departureeff. 2025-09-01
- Roger Dansey · director · appointment
- Roy D. Baynes · director · appointment
Latest filings
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-06-08
- 8-K · Company announcement2026-05-15
- 10-Q · Quarterly report2026-04-08
- 8-K · Company announcement2026-04-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Nurix Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.